<DOC>
	<DOCNO>NCT02615938</DOCNO>
	<brief_summary>This exploratory Phase 2a , randomize , double-blind , placebo-controlled , parallel-group , multinational study investigate initiation withdrawal hydroxychloroquine subject chILD .</brief_summary>
	<brief_title>Hydroxychloroquin ( HCQ ) Pediatric Interstitial Lung Disease ( ILD )</brief_title>
	<detailed_description>This study explorative , prospective , randomize , double-blind , placebo control investigation hydroxychloroquine ( HCQ ) pediatric ILD . The treatment organize START STOP block , initiate sequence , need subject . Each patient participate block . In START block subject randomize parallel-groups , placebo group switch active drug . In STOP block , subject HCQ randomize parallel-groups treat placebo HCQ investigate withdrawal HCQ assessment efficacy .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients clinically stable baseline ( Visit 1 2 ) inclusion study 1 . To determine , attend physician use SpO2 room air patient room air O2supplement ; absolute difference SpO2 expect ≥ 5 % Visit 1 2 . For patient respiratory support , summary key parameter change ≥ 20 % Visit 1 2 2 . No major change medication Visit 1 2 2 . Mature newborn ≥ 37 week gestation , age ≥ 3 wks infant child ( till age 18 ) previously preterm ( ≤ 37 week gestation ) baby child adult age chILD genetically diagnose ( see inclusion criterion 3 . ) 3 . Diagnosis chronic ( ≥ 3 wks duration ) diffuse parenchymal lung disease ( DPLD = chILD ) , define least one follow way : 1. chILD genetically diagnose Surfactant dysfunction disorder include patient disease cause mutation SFTPC , SFTPB , ABCA3 , TTF1 ( Nkx21 ) , extremely rare entity . In case , also previously preterm ( ≤ 37 week gestation ) baby child adult age include study . 2. chILD histologically diagnose Chronic pneumonitis infancy ( CPI ) Desquamative interstitial pneumonia ( DIP ) Lipoid pneumonitis Cholesterol pneumonia Nonspecific interstitial pneumonia ( NSIP ) PAP exclusion mutation GMCSFRa/b GMCSF autoantibodies Microvasculopathy Cryptogenic Organizing Pneumonia Diffuse Alveolar Damage Acute Interstitial Pneumonia Acute Fibrinous Organizing Pneumonia Respiratory BronchiolitisInterstitial Lung Disease Usual interstitial pneumonia ( UIP ) Sarcoidosis Follicular bronchitis/bronchiolitis/Lymphocytic interstitial pneumonia ( LIP ) unless associate immunodeficiency Giant cell interstitial pneumonia ( GIP ) Storage disease primary pulmonary involvement ( e.g . Niemann Pick ) Pulmonary interstitial glycogenosis ( cellular interstitial pneumonitis , histiocytoid pneumonia ) Neuroendocrine cell hyperplasia infancy ( NEHI ) HermanskyPudlak Syndrome Hypersensitivity pneumonitis ( suitable Stop EAA study chILDconsortium ) Other histology diagnose chILD 3. chILD clinically diagnose Unclear RDS mature newborn , exclusion far possible infectious , lung structural , vascular know cause chILD ; presence radiological evidence chILD ; presence either tachypnoea , dyspnoea oxygen requirement , need mechanical ventilation . Idiopathic pulmonary haemorrhage ( haemosiderosis ) 4 . Start block : HCQ treatment last 12 week Stop block : stable HCQ treatment least last 12 week 5 . Ability subject or/and legal representative understand character individual consequence clinical trial . 6 . Signed date informed consent subject ( subject ability ) representative ( underaged child ) must available start specific trial procedure . Exclusion criterion : chILD primarily relate developmental disorder chILD primarily relate growth abnormality reflect deficient alveolarisation chILD relate chronic aspiration chILD related immunodeficiency chILD related abnormality lung vessel structure chILD relate organ transplantation/organ rejection/GvHD chILD relate recurrent infection Acute severe infectious exacerbation Known hypersensitivity HCQ , ingredient tablet ( lactosemonohydrate , povidone , maize starch , magnesium stearate , hypromellose , macrogol titanium dioxide ( E 171 ) , silicon dioxide mannitol ) , sucroseoctaacetate sodium saccharine . Proven retinopathy maculopathy Glucose6phosphatedehydrogenase deficiency result favism hemolytic anemia Myasthenia gravis Hematopoetic disorder Pregnancy lactation ( Women childbearing potential practice medically accept contraception trial till three month end treatment HCQ , negative pregnancy test ( serum urine ) existent trial . Reliable contraception systematic contraceptive ( oral , implant , injection ) . Women sterile surgery participate trial ) . Participation clinical trial present clinical trial beyond time 4 halflives medication use , least one week . Hereditary galactose intolerance , lactase deficiency glucosegalactosemalabsorption Renal insufficiency screening , define glomerular filtration rate ( GFR ) &lt; 40 mL/min/1.73 m2 patient age 3 8 week &lt; 60 mL/min/1.73 m2 patient ≥ 8 week age ( KDIGO guideline 2012 , K/DOQI guideline 2002 ) Liver disease , gastrointestinal disorder , haematological disorder , epilepsy neurological disorder , psoriasis , porphyria discretion treat physician Simultaneous prescription potentially nephrotoxic hepatotoxic medication discretion treat physician</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>